SCHEMBL6741228

SCHEMBL6741228

CCC1(CC)OC(=O)c2cc(N)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
FTO Q9C0B1 1/20 0.47
POLB P06746 2/20 0.38
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
CYP3A4 P08684 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
TSHR P16473 2/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
PTPRC P08575 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 2/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
PLA2G1B P04054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6742481 0.77 MEN1 (0.54) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL6739516 0.77 SMN1; SMN2 (0.50) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL10595270 0.75 MEN1 (0.58) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL28716946 0.72 NPSR1 (0.44) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL20536883 0.71 MEN1 (0.76) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL10531285 0.71 ELOVL6 (0.42) PGR
SCHEMBL11826152 0.71 MEN1 (0.48) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL9190550 0.70 MEN1 (0.74) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL29922159 0.70 POLB (0.39) MEN1KMT2AFTOPOLBALDH1A1
SCHEMBL9776773 0.69 MEN1 (0.56) MEN1KMT2AFTOPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689808-B2 TREATING OR PREVENTING EPILEPSY OR NEURODEGENERATIVE DISEASES LES LABORATOIRES SERVIER (FR) 2004-02-10 US claimed
US-20030220393-A1 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2003-11-27 US claimed
EP-1320528-A2 SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2003-06-25 EP claimed
WO-2002000638-A2 SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS INSTITUTE OF MATERIA MEDICA (CN) 2002-01-03 WO claimed
US-6689808-B2 TREATING OR PREVENTING EPILEPSY OR NEURODEGENERATIVE DISEASES LES LABORATOIRES SERVIER (FR) 2004-02-10 US disclosed
US-20030220393-A1 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2003-11-27 US disclosed
EP-1320528-A2 SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2003-06-25 EP disclosed
WO-2002000638-A2 SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS INSTITUTE OF MATERIA MEDICA (CN) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220393-A1 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them NR5A2, NR2E3, NR4A1 MEN1 2571/4885KMT2A 1077/4885FTO 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.